| Literature DB >> 35676526 |
Nigusie Gashaye Shita1, Ashagrie Sharew Iyasu2.
Abstract
Poor glycemic control is a main public health problem among type 2 diabetes mellitus (T2DM) patients and a significant cause of the development of diabetic complications. This study aimed to assess the glycemic control status and its associated factors among type 2 diabetes patients in Felege-Hiwot and Debre Markos Referral Hospitals. A retrospective cohort study was conducted at Felege-Hiwot and Debre Markos Referral Hospitals from December 2014 to December 2015. We have reviewed the chart of these patients until January 2020. Type 2 diabetic patients on follow-up at Felege-Hiwot and Debre Markos Referral Hospitals who fulfilled the inclusion criteria of the study were included. The primary outcome was the level of blood glucose during the study period. Good glycemic control was defined as patients whose average fasting blood glucose measurement for three consecutive visits was between 70 and 130 mg/dL. A generalized linear mixed autoregressive order one model was used to identify the determinants of glycemic control. A total of 191 patients with 1740 observations were included in the study. The overall prevalence of good glycemic control was 58.4% (95% CI: 57.159.7%). The factors associated with good glycemic control at 95% confidence level adjusted odds ratio were being residing in rural (CI: 0.454, 0.614), negative proteinuria (CI: 1.211, 1.546), diastolic blood pressure < 90 (CI: 1.101, 1.522), systolic blood pressure < 140 (CI: 1.352, 1.895), serum creatinine (CI: 0.415, 0.660), duration per visit (CI: 0.913, 0.987), duration since diagnosis (CI: 0.985, 0.998), weight ≥ 78 kg (CI: 0.603, 0.881). Age 38-50, 51-59 and 60-66 years (CI: 1.267, 1.776), (CI: 1.057, 1.476) and (CI: 1.004, 1.403), respectively. The overall prevalence of poor glycemic control was high at Debre Markos and Felege Hiwot Referral Hospital. Living in a rural area, older age (≥ 67 years), positive proteinuria, higher weight (≥ 78 kg), higher serum creatinine levels, higher duration per visit, higher time duration of T2DM since diagnosis, and developing hypertension (SBP ≥ 140, DBP ≥ 90) were the predictors of lower good glycemic control achievements of T2DM patients. In response to this finding, an aggressive intervention that targets improving glycemic control is required.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35676526 PMCID: PMC9177638 DOI: 10.1038/s41598-022-13673-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Population characteristics for 191 type 2 DM patients with 1740 glycimic control stataus observations at Felege Hiwot and Debre Markos Referral Hospital, December 2014-January 2020.
| Variable | Categories | Frequency (%) |
|---|---|---|
| Gender | Female | 73(38.2) |
| Male | 118(61.8) | |
| Residence | Rural | 47(24.6) |
| Urban | 144(75.4) | |
| Age in years | Mean (± SD) | 57.89(± 10.47) |
| Weight in kg | Mean (± SD) | 73.29(± 5.53) |
| DBP in mm Hg | Mean (± SD) | 78.50(± 11.45) |
| SBP in mm Hg | Mean (± SD) | 124.85(± 17.49) |
| FBS in mg/dl | Mean (± SD) | 137.35(± 81.64) |
| Hypertension comorbidity | Yes | 122(63.9) |
| No | 69(36.1) | |
| Diabetic complication | Retinopathy | 26(13.6) |
| Nephropathy | 38(19.9) | |
| Neuropathy | 30(15.7) | |
| Stroke | 8(4.2) | |
| Coronary artery disease | 19(9.9) | |
| Prepral artery disease | 5(2.6) | |
| No | 65(34) |
Cross tabulation and Univariate analysis of glycemic control status for 191 patients with 1740 glycimic control status observations at DMRH and FHRH, December 2014–January 2020.
| Variable | Catagories | Overall proportion of Glycemic control from total observation | p-value | |
|---|---|---|---|---|
| Poor (%) | Good (%) | |||
| Gender | Female | 259(35.8) | 368(36.2) | 0.833 |
| Male | 465(64.2) | 648(63.8) | ||
| Residence | Rural | 180(24.9) | 143(14.0) | < 0.000 |
| Urban | 544(75.1) | 873(86.0) | ||
| Age | 38–50 | 176(24.3) | 318(31.3) | 0.001 |
| 51–59 | 179(24.7) | 237(23.3) | ||
| 60–66 | 176(24.2) | 231(22.8) | ||
| 67–80 | 194(26.8) | 230(22.6) | ||
| Treatment | Insulin alone or insulin plus oral agents | 123(17.0) | 193(19.0) | 0.522 |
| More than one oral agent | 104(14.4) | 161(15.9) | ||
| One oral agent | 497(68.6) | 661(65.1) | ||
| Proteinurea | Negative | 328(45.3) | 576(56.7) | < 0.000 |
| Positive | 396(54.7) | 440(43.3) | ||
| Weight | 58–69 | 105(14.5) | 380(37.4) | 0.069 |
| 70–73 | 139(19.1) | 253(24.9) | ||
| 74–77 | 219(30.2) | 217(21.4) | ||
| 78–87 | 262(36.2) | 166(16.3) | ||
| DBP | < 90 | 479(66.1) | 778(76.6) | 0.001 |
| ≥ 90 | 245(33.9) | 238(23.4) | ||
| SBP | < 140 | 498(68.6) | 827(81.4) | < 0.000 |
| ≥ 140 | 226(31.2) | 189(18.6) | ||
| Creatinine, mg/dl | Mean (± SD) | 1.26(± 0.28) | 1.21 ± (0. 27) | < 0.000 |
| Duration per visit, months | Mean (± SD) | 1.5(± 1.7) | 1.4(± 1.3) | 0.002 |
| Duration since diagnosis, months | Mean (± SD) | 43.1(± 9.9) | 43.4(± 9.3) | 0.043 |
Figure 1Fluctuation in glycemic control over time among type 2 diabetes patients at Felege Hiwot and Debre Markos Referral Hospital, December 2014–January 2020.
Results of Generalized Linear Mixed model with logit link for factors associated with glycemic control for 191 type 2 diabetes mellitus patients with 1740 glycimic control status observations.
| Variables | COR (95%CI) | Multivariable analysis | ||
|---|---|---|---|---|
| AOR (95%CI) | P-value | |||
| Residence | Rural | 0.492(0.427, 0.567) | 0.528(0.454, 0.614) | < 0.000 |
| Urban (ref) | ||||
| Age | ≤ 50 | 1.521(1.303, 1.774) | 1.500(1.267, 1.776) | < 0.000 |
| 51–59 | 1.115(0.952, 1.306) | 1.249(1.057, 1.476) | 0.027 | |
| 60–66 | 1.111(0.947, 1.302) | 1.187(1.004, 1.403) | 0.030 | |
| ≥ 67 (ref) | ||||
| Proteinurea | Negative | 1.580(1.412, 1.769) | 1.368(1.211,1.546) | < 0.000 |
| Positive(ref) | ||||
| Weight | ≤ 69(ref) | |||
| 70–73 | 0.865(0.710, 1.054) | 0.947(0.766, 1.171) | 0.315 | |
| 74–77 | 0.794(0.677, 0.932) | 0.898(0.757, 1.064 ) | 0.764 | |
| ≥ 78 | 0.543(0.457, 0.645) | 0.729(0.603, 0.881) | 0.015 | |
| DBP | < 90 | 0.678(1.484, 1.898) | 1.295(1.101, 1.522) | 0.001 |
| ≥ 90 (ref) | ||||
| SBP | < 140 | 1.981(.740, 2.256) | 1.601(1.352, 1.895) | < 0.000 |
| ≥ 140 (ref) | ||||
| Creatinine | continuous | 0.452(0.365, 0.561) | 0.523(0.415, 0.660) | < 0.000 |
| Duration per visit | Continous | 0.943(0.908, 0.980) | 0.949(0.913, 0.987) | 0.002 |
| Duration since diagnosis | Continous | 1.004(0.998, 1.010) | 0.992(0.985, 0.998) | 0.042 |
| Time | Continous | 1.011(1.006, 1.016) | 1.014(1.010, 1.019) | < 0.000 |
| Cov Parm | Subject | Estimate | Standard Error | |
| AR (1) | ID | 0.215 | 0.014 | |
| Residual | 0.997 | 0.020 | ||
AR (1) autoregressive order one, AOR adjusted odd ratio, COR crud odd ratio, CovParm covariance parameter, DBP diastolic blood pressure, SBP systolic blood pressure, ref reference group, 95%CI 95% Confidence interval, P-value Probability value.
Figure 2Summary of study participants recruiting flow chart.
Summarized value of Information criteria for 191 type 2 diabetes mellitus patients with 1740 glycimic control status observations at DMRH and FHRH, December 2014–December 2020.
| Covariance structure | AIC | BIC | Generalized Chi-Square | Gener. Chi-Square / DF |
|---|---|---|---|---|
| Constant variance | 22,726.33 | 22,726.53 | 5253.29 | 1.00 |
| Compound symmetry | 22,877.57 | 22,877.97 | 5299.18 | 1.01 |
| Autoregressive order one | 22,458.78 | 22,459.18 | 5251.35 | 1.00 |
| Toeplitz | 22,459.18 | 22,460.28 | 5252.52 | 1.00 |
| Unstructured | 22,890.72 | 22,891.32 | 5301.35 | 1.00 |